)
Chemo Pharma Laboratories (506365) investor relations material
Chemo Pharma Laboratories Q2 25/26 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Board approved unaudited standalone financial results for the quarter and half year ended September 30, 2025, with review by the audit committee and limited review by auditors.
No subsidiaries and only one operating segment reported.
Financial highlights
Revenue from operations for Q2 FY26 was ₹5,256.56 thousand, compared to nil in the previous quarter.
Total revenue for the half year ended September 30, 2025, was ₹6,310.00 thousand.
Net profit for Q2 FY26 was ₹980.14 thousand, compared to a net loss of ₹118,050.65 thousand in Q1 FY26.
Earnings per share for Q2 FY26 stood at ₹0.65, compared to -₹78.70 in Q1 FY26.
Key financial ratios and metrics
Equity share capital remained at ₹15,000.00 thousand as of September 30, 2025.
Total assets as of September 30, 2025, were ₹20,578.35 thousand, down from ₹133,498.52 thousand as of March 31, 2025.
Total equity as of September 30, 2025, was ₹14,375.71 thousand.
- TimeTickerHeadlineOpen
- 6 FebCRI
Revenue up sharply, net loss reduced, and strong cash inflow from share issue and contracts. - 6 FebSCW
Q3 2025 revenue up 39% y/y, backlog at 58.3 mln PLN, and new strategy for optical payloads. - 6 FebSCW
73% revenue growth and record backlog driven by new space contracts and strategic investments. - 6 FebSCW
Record revenue, surging backlog, and major space contracts set the stage for 2025 growth. - 6 FebSCW
Q1 2025 revenue nearly doubled year-over-year, with strong backlog and major new contracts secured. - 6 FebSCW
Record Q2 revenue, major new contracts, and a tripled backlog signal strong growth. - 6 FebNVDA
AI-driven virtual twins and accelerated computing are revolutionizing design and manufacturing. - 6 FebSPKSJF
Record income, strong growth, and robust capital position despite lower interest income. - 6 FebISCTR
Net profit hit TL 67.4 billion in 2025, with strong NIM, fee growth, and solid 2026 outlook. - 6 FebCDP
2025 FFO/share rose 5.8% with strong leasing and retention; 2026 guidance signals further growth.
Next Chemo Pharma Laboratories earnings date
Next Chemo Pharma Laboratories earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage
)
)